Biomarkers can be highly misleading, even though they provide...

First 43 Last

Share
Profile

Follow
Sabbath

9,677 Posts.

335

10/06/21

16:57

Post #: 53774432
Share
Originally posted by Charles89 ↑

"I'm not even sure they have already selected the final markers that will be targeted in the test."

I believe they have:

In previous studies, biomarkers such as procalcitonin (PCT), interleukin 6 (IL-6) and interleukin 8 (IL-8) have been proposed as promising candidates for sepsis determination, in addition to the conventional testing of C-reactive protein (CRP) and lactate levels as well as leukocyte
counts (Faix, J.D., 2013). PCT, IL-6 and CRP were used as the biomarkers for the development of AnteoTech’s sepsis test. Several references were selected and described below:

PCT - pre-cursor to calcitonin. Levels rise in response to bacterial infection and tissue injury though typically see a significant increase during systemic bacterial infection and sepsis (Yunus et al., 2018). Listed as a diagnostic criteria for sepsis as part of the Surviving Sepsis Campaign (Dellinger et al., 2008).

IL-6 - an initial response cytokine released in response to trauma. Whilst not specific to sepsis, IL-6 production is seen to increase during sepsis and levels are significantly higher in those experiencing septic shock than those without. Amongst the cytokines produced during sepsis, plasma IL-6 displayed with best correlation with mortality rates (Chaudry et al., 2013).

CRP - a non-specific marker for infection and inflammation, significant and rapid increases in CRP can be observed during the early onset of sepsis and fall quickly with successful treatment (Faix, J.D., 2013). Listed as a diagnostic criteria for sepsis as part of the Surviving Sepsis Campaign.

"A Proof of Concept full-strip lateral flow assay for the detection of sepsis markers was achieved, with promising results suggesting that with further work a viable product could be developed."

Expand

Biomarkers can be highly misleading, even though they provide some evidence of an underlying condition they in no way limit that condition once identified. Having a test is one thing have a treatment is another. I don't believe ADO has the clinical capability to advance beyond providing 'sepsis may be evident' stage nor how advanced it is.
ADO Price at posting: 27.0¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply